Viz.ai, a San Francisco, CA- and Tel Aviv, Israel-based developer of a synchronized healthcare software (Viz) using artificial intelligence (AI), raised $50m in Series B funding.
The round was led by Greenoaks with participation from Threshold Ventures, CRV along with existing investors GV and Kleiner Perkins.
The company intends to use the funds to bring A.I. powered synchronized stroke care to expanding geographies.
Led by Chris Mansi, CEO, Viz.ai applies artificial intelligence to improve how healthcare is delivered through intelligent software that promises to reduce time to treatment and improve access to care. Its flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about suspected stroke patients straight to a specialist who can intervene and treat.
In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO. The company announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers a tool for automated cerebral perfusion image analysis.
Viz.ai’s acute ischemic stroke software is now available in over 300 hospitals across the U.S.